A5068912186- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Medical Imaging Techniques and Applications
- Prostate Cancer Treatment and Research
- Graphene and Nanomaterials Applications
- Carbon Nanotubes in Composites
- Radiation Therapy and Dosimetry
- Advanced biosensing and bioanalysis techniques
- RNA Interference and Gene Delivery
- Chemical Reactions and Isotopes
- CAR-T cell therapy research
- Mass Spectrometry Techniques and Applications
- Metal complexes synthesis and properties
- Cancer Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Immunotherapy and Immune Responses
- Nanoplatforms for cancer theranostics
- Lung Cancer Treatments and Mutations
- Neuroblastoma Research and Treatments
- Medical Imaging and Pathology Studies
- Nanoparticle-Based Drug Delivery
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Catalytic Processes in Materials Science
- Glioma Diagnosis and Treatment
Memorial Sloan Kettering Cancer Center
2015-2024
Cornell University
2010-2024
Kettering University
2002-2020
Weill Cornell Medicine
2017-2018
Actinium Pharmaceuticals (United States)
2013
Skinfrared (United States)
2012
Massachusetts General Hospital
2011
Johns Hopkins University
2004-2010
University of Baltimore
2010
University at Albany, State University of New York
2008
A single, high linear energy transfer alpha particle can kill a target cell. We have developed methods to molecular-sized generators of alpha-emitting isotope cascades the inside cancer cells using actinium-225 coupled internalizing monoclonal antibodies. In vitro, these constructs specifically killed leukemia, lymphoma, breast, ovarian, neuroblastoma, and prostate at becquerel (picocurie) levels. Injection single doses kilobecquerel (nanocurie) levels into mice bearing solid carcinoma or...
Single-walled carbon nanotubes (CNT) are mechanically robust graphene cylinders with a high aspect ratio that comprised of sp<sup>2</sup>-bonded atoms and possessing highly regular structures defined periodicity. CNT exhibit unique mechanochemical properties can be exploited for the development novel drug delivery platforms. We hypothesized prototype nanostructures consisting biologics, radionuclides, fluorochromes, could synthesized designed to target tumor cells. <b>Methods:</b>...
The potential of alpha-particle emitters to treat cancer has been recognized since the early 1900s. Advances in targeted delivery radionuclides and radionuclide conjugation chemistry, increased availability alpha-emitters appropriate for clinical use, have recently led patient trials radiopharmaceuticals labeled with emitters. Although studied many decades, their current use humans therapy is an important milestone. objective this work review those aspects field that are pertinent emitter...
Tumors build vessels by cooption of pre-existing vasculature and de novo recruitment bone marrow (BM)-derived endothelial progenitor cells (EPCs). However, the contribution functional role EPCs in tumor neoangiogenesis are controversial. Therefore, using genetically marked BM cells, we demonstrate precise spatial temporal to neovascularization three transplanted one spontaneous breast vivo high-resolution microscopy flow cytometry. We show that early tumors recruit BM-derived differentiate...
The molecular weight cutoff for glomerular filtration is thought to be 30–50 kDa. Here we report rapid and efficient of molecules 10–20 times that mass a model the mechanism this filtration. We conducted multimodal imaging studies in mice investigate renal clearance single-walled carbon nanotube (SWCNT) construct covalently appended with ligands allowing simultaneous dynamic positron emission tomography, near-infrared fluorescence imaging, microscopy. These SWCNTs have length distribution...
Lintuzumab (HuM195), a humanized anti-CD33 antibody, targets myeloid leukemia cells and has modest single-agent activity against acute (AML). To increase the potency of antibody without nonspecific cytotoxicity associated with β-emitters, α-particle-emitting radionuclide bismuth-213 ((213)Bi) was conjugated to lintuzumab. This phase I/II trial conducted determine maximum tolerated dose (MTD) antileukemic effects (213)Bi-lintuzumab, first targeted α-emitter, after partially cytoreductive chemotherapy.
The potential medical applications of nanomaterials are shaping the landscape nanobiotechnology field and driving it forward. A key factor in determining suitability these must be how they interface with biological systems. Single walled carbon nanotubes (CNT) being investigated as platforms for delivery biological, radiological, chemical payloads to target tissues. CNT mechanically robust graphene cylinders comprised sp(2)-bonded atoms possessing highly regular structures defined...
Long-term survival still eludes most patients with leukemia and non-Hodgkin's lymphoma. No approved therapies target the hallmark of B cell, its mIgM, also known as B-cell receptor (BCR). Aptamers are small oligonucleotides that can specifically bind to a wide range molecules offer some advantages over antibodies therapeutic agents. Here, we report rational engineering aptamer TD05 into multimeric forms reactive BCR may be useful in biomedical applications. Systematic truncation coupled...
Abstract: Single wall carbon nanotube (SWCNT) constructs were covalently appended with radiometal-ion chelates (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [DOTA] or desferrioxamine B [DFO]) and the tumor neovascular-targeting antibody E4G10. The E4G10 specifically targeted monomeric vascular endothelial-cadherin (VE-cad) epitope expressed in angiogenic vessels. construct specific activity blood compartment clearance kinetics significantly improved relative to corresponding...
Fibrillar carbon nanotubes simultaneously deliver two small interfering RNAs, which safely prevent acute kidney injury and prolong survival in mice.
Abstract Purpose: The anti-CD33 antibody lintuzumab has modest activity against acute myeloid leukemia (AML). To increase its potency, was conjugated to actinium-225 (225Ac), a radionuclide yielding 4 α-particles. This first-in-human, phase I trial conducted determine the safety, pharmacology, and biological of 225Ac-lintuzumab. Patients Methods: Eighteen patients (median age, 64 years; range, 45–80) with relapsed or refractory AML received single infusion 225Ac-lintuzumab at activities 18.5...